Acadia Pharma (ACAD) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
May 7, 2020 4:07 PM EDT- 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19
- On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer
- Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system (CNS) therapeutic program
- 2020 revenue guidance reduced by approximately 5% due to currently anticipated COVID-19 impact
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative... More
